Turn Therapeutics Inc.

Turn Therapeutics Inc. (TTRX) shows no detected cyber incidents or material red-flag 8-K filings in our 90-day monitoring window. However, absence of recent events does not indicate absence of risk; a clinical-stage biotech faces structural vulnerabilities including equity dilution pressure, financing dependency, and cash-burn dynamics that require deeper analysis. The full $49 Report extends the lookback to 12 months, calculates dilution risk scores across funding rounds, maps the complete 8-K and financing history, and flags AI-detected risk signals in SEC filings that our real-time pipeline may not surface. The full $49 Report adds quantified dilution trajectory, 12-month filing context, and forward risk signals that matter for position sizing.